Login / Signup

Development of a long noncoding RNA-based machine learning model to predict COVID-19 in-hospital mortality.

Yvan DevauxLu ZhangAndrew I LumleyKanita Karaduzovic-HadziabdicVincent MooserSimon RousseauMuhammad ShoaibVenkata P SatagopamMuhamed AdilovicPrashant Kumar SrivastavaCostanza EmanueliFabio MartelliSimona GrecoLina BadimónTeresa PadróMitja LustrekMarkus ScholzMaciej RosolowskiMarko JordanTimo BrandenburgerBettina BenczikBence AggPeter FerdinandyJörg Janne VehreschildBettina Lorenz-DepiereuxMarcus DörrOliver WitzkeGabriel SanchezSeval KulAndrew H BakerGuy FagherazziMarkus OllertRyan WereskiNicholas L MillsHüseyin Firat
Published in: Nature communications (2024)
Tools for predicting COVID-19 outcomes enable personalized healthcare, potentially easing the disease burden. This collaborative study by 15 institutions across Europe aimed to develop a machine learning model for predicting the risk of in-hospital mortality post-SARS-CoV-2 infection. Blood samples and clinical data from 1286 COVID-19 patients collected from 2020 to 2023 across four cohorts in Europe and Canada were analyzed, with 2906 long non-coding RNAs profiled using targeted sequencing. From a discovery cohort combining three European cohorts and 804 patients, age and the long non-coding RNA LEF1-AS1 were identified as predictive features, yielding an AUC of 0.83 (95% CI 0.82-0.84) and a balanced accuracy of 0.78 (95% CI 0.77-0.79) with a feedforward neural network classifier. Validation in an independent Canadian cohort of 482 patients showed consistent performance. Cox regression analysis indicated that higher levels of LEF1-AS1 correlated with reduced mortality risk (age-adjusted hazard ratio 0.54, 95% CI 0.40-0.74). Quantitative PCR validated LEF1-AS1's adaptability to be measured in hospital settings. Here, we demonstrate a promising predictive model for enhancing COVID-19 patient management.
Keyphrases